Position of the Transparency Council – Keytruda (pembrolizumab)
At its meeting on 9 June 2025, the Transparency Council adopted position No. 69/2025 on the appraisal of drug Keytruda (pembrolizumab) under the drug program “B.148. Treatment of patients with endometrial cancer (ICD-10: C54)”